Other studies have shown that in breast, ovarian, and gastric cancer, the loss in cancer cell SDC-1 is accompanied by increased stromal SDC-1 expression and adverse clinical outcome [61], [62], [63], [64]. Here, SDC1 is linked to gastric cancer.